Ozoralizumab, a Humanized Anti-TNFα NANOBODY® Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an…

Overview of attention for article published in Frontiers in immunology, February 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

blogs: 1 blog
twitter: 4 X users

patent: 1 patent

Citations

dimensions_citation: 56 Dimensions

Readers on

mendeley: 57 Mendeley

Summary Blogs X Patents Dimensions citations

So far, Altmetric has seen 1 blog post.

Ozoralizumab

New Drug Approvals, 12 Oct 2022

Ozoralizumab FormulaC1682H2608N472O538S12CAS 1167985-17-2Mol weight38434.3245 PMDA JAPAN APPROVED 2022 2022/9/26 Nanozora…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.